Femasys Did Not Raise $30 Million. That Headline Is Stale. The Cash Problem Is Real.

The claim that Femasys (NASDAQ: FEMY) has secured a $30 million private placement with potential proceeds of up to $90 million does not hold up to the filings. There is no such deal. The most recent financing is a $12 million senior secured convertible note agreement from November 2025, with potential proceeds of up to $58 million if all attached warrants are exercised for cash. The $30/$90 figure is either a conflation of separate financings or a fabrication.

That distinction matters. If you are reading a headline and assuming Femasys just solved its liquidity problem, you are anchoring to a number that doesn't exist. The actual cash situation is tighter.

The old story the market has been told

Femasys has been raising capital in small increments for years. A $4.5 million public offering and private placement in May 2025. An $8 million underwritten public offering in August 2025. The $12 million convertible note deal in November 2025, structured in two tranches and carrying an 8.5% pay-in-kind interest rate (interest that compounds into the principal rather than being paid in cash). In March 2026, the company amended those notes and issued a fresh tranche of Series D-1 warrants to existing lenders at an exercise price of $0.58 per share — effectively printing more dilution to keep the current debt facility intact.

The company's lead lender is Pointillist Partners, associated with Clearpath CEO Jorey Chernett. The lead lender agreement includes a board nomination right and a 30% beneficial ownership cap. This is not a broad-based institutional commitment; it is a concentrated relationship with a single creditor who also sits on the board.

The proof path: cash burn versus revenue

As of March 31, 2026, Femasys held $5.4 million in cash. The company burned approximately $3.9 million in the quarter alone, taking its cash balance from $9.3 million at year-end to $5.4 million in three months. Management said those resources would fund operations into the third quarter of 2026. We are now at the end of the third quarter. That runway is either being consumed now or has already expired.

Revenue tells the other side of the ledger. Total sales in Q1 2026 were $424,889 — up 24.5% from $341,264 a year earlier. The increase was primarily driven by FemBloc, which has received regulatory approval in Europe (June 2025), the UK (August 2025), and New Zealand (September 2025) and is being commercialized through partnerships. But $425,000 in quarterly revenue against a $3.9 million quarterly cash burn means the business is not close to self-funding. It is not close to being close.

The net income of $846,100 that the company reported for the quarter is not a sign of operating health. It was driven by $5.1 million in non-cash fair value gains on conversion option and warrant liabilities — accounting fluctuations that move with the stock price and do not represent cash entering the bank account. The operating loss was $4.2 million.

Why the tape is misleading

The stock went through a one-for-20 reverse split on June 8, 2026, after Nasdaq granted an extension until July 13, 2026, for the company to regain compliance with the $1.00 minimum bid price requirement. A reverse split is a cosmetic exercise: it reduces the number of shares and raises the per-share price without changing the company's market capitalization or business fundamentals. The stock closed around $2.66 today (post-split), down nearly 10% on the session. Market capitalization is in the low tens of millions.

A one-for-20 reverse split is what you do when you are fighting to stay listed. The accumulated deficit sits at approximately $145 million.

What the operating side is actually doing

The one thing that is genuinely improving is the product pipeline. FemBloc — a non-surgical permanent birth control device — has regulatory approval outside the U.S. and is in the final enrollment phase of its U.S. pivotal FINALE trial (Part B). FDA Investigational Device Exemption approval for Part B enrollment was granted in November 2025, and enrollment is ongoing. FemaSeed, the company's infertility treatment product, is also being advanced.

The European approvals give Femasys a real commercial beachhead. The inventory balance rose to $6.1 million in Q1 2026, up from $5.7 million, as development products transitioned to commercial inventory. R&D expenses dropped 56% year-over-year to $1.3 million, reflecting that shift from research to commercialization. These are the right directional moves.

But the U.S. market is where the valuation lives. And U.S. FDA approval for FemBloc is still a clinical trial and a Pre-Market Approval submission away — with no public timeline.

The break condition

The setup here is not an inflection play. It is a binary event play with a liquidity tail risk. The inflection would be FDA approval of FemBloc, which would unlock U.S. commercial revenue and potentially make the existing European approvals look like a rounding error. But until that happens, the company needs capital to stay alive.

If you are in this position, the question is not about a phantom $30 million raise. It is about whether the $5.4 million cash balance from March stretches far enough for another capital event that doesn't wipe out existing shareholders. The 8.5% PIK debt is already compounding. The warrant structure from the November deal includes three exercise tiers ($0.81, $0.92, and $1.10 per share) that expire on triggered conditions — including FDA approval of FemBloc for the Series C-1 warrants, which would force conversion at a steep discount to any post-approval price.

The tripwire is straightforward: if Femasys announces a dilutive equity raise at a price well below the current $2.66 level, the thesis that the market is undervaluing the FemBloc pipeline breaks. The capital-raicing cycle on a falling stock eats the optionality.

Conversely, if the FINALE Part B trial data readout lands and supports a PMA submission on a credible timeline, the current share price reflects a company that is priced for failure while the European commercialization and U.S. trial machinery keep moving. The market bar is at zero. That creates room for surprise if the clinical data cooperates.

But until then, this is not a free cash flow story. It is a binary event with a cash countdown. Sit on your hands until the capital structure clears or the FDA data arrives — then decide which way the coin lands.